on GBC Kapital GmbH
GBC Kapital Supports Marinomed's Capital Increase Success
Marinomed Biotech AG has completed a significant capital increase, supported by GBC Kapital GmbH. This success marks a crucial financial milestone for the listed biotechnology company headquartered in the German-speaking region. Marinomed, traded under ISIN: ATMARINOMED6 and WKN: A2N9MM, aims to use this financial bolster to advance its strategic and operational development efforts, especially for its lead products Budesolv and Tacrosolv.
This move increases Marinomed's financial flexibility and underscores investor confidence in its technology platform and future growth. GBC Kapital's role in this transaction follows its successful support in the December 2025 full placement of A.H.T. Syngas Technology N.V.'s convertible bond, showing their continued prowess in customized financing solutions for companies.
The newly issued shares will soon commence trading on the Vienna Stock Exchange, subject to standard formalities.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all GBC Kapital GmbH news